Sanofi and Regeneron Pharmaceuticals announced positive results from two Phase IIIb/IV ODYSSEY-DM trials in patients with diabetes. In the studies,...
The results of the Phase III EINSTEIN-PE 4,833-patient study have been presented at the American College of Cardiology meeting in...
The emphasis in these Guidelines is to provide information on the current state of the art in how to prevent and manage the diverse problems associated with the effects of DM (Diabetes Mellitus) on the heart and vasculature in a holistic manner.
BMS and Pfizer Inc. announced the FDA has approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the...
Bayer HealthCare's oral anticoagulant Xarelto (rivaroxaban) has been approved by the European Commission (EC) for the treatment of Pulmonary Embolism...
The CHMP of the European Medicines Agency has issued a positive opinion recommending approval of Pradaxa (dabigatran etexilate), from Boehringer,...
A pooled analysis of the Phase III EINSTEIN trial program, shows Xarelto (rivaroxaban), from Janssen/Bayer HealthCare, is as effective as...
The task force aimed to: (1) develop evidence-based recommendations for patient education (PE) for people with inflammatory arthritis, (2) identify the need for further research on PE and (3) determine health professionals’ educational needs in order to provide evidence-based PE.
The National Institute for Health and Care Excellence (NICE) has published final guidance endorsing Pradaxa (dabigatran etexilate) from Boehringer for...